Zelira Therapeutics Ltd. announced that the University of Western Australia's investigational team that undertook the double-blind, placebo controlled, cross-over trial of Zelira's ZTL-101 (on market as Zenivol) in chronic insomnia patients has had the results of its trial published in the peer-reviewed journal SLEEP. As outlined in the manuscript, chronic insomnia is present in between 6-15% of the population and is associated with adverse health outcomes. Current pharmacological treatment options are often unsatisfactory with significant side effects. The published results demonstrated that following 2-weeks of using Zelira's ZTL-101, patients saw a significant decrease in insomnia symptoms relative to placebo.